|  |  |  |  |
| --- | --- | --- | --- |
| Supplementary Table 2 Patient, tumor and treatment characteristics by adverse events related to surgery | | | |
|  | **Adverse events related to surgery = YES**  **N=203** | **Adverse events related to surgery = NO**  **N=233** | **p-value** |
| Age, median (Q1 – Q3), yrs | 58.0 (48.0 – 69.0) | 61.0 (51.0 – 71.0) | 0.072 |
| BMI, median (Q1 – Q3), kg/m2° | 24.55 (21.3 – 28.0) | 24.2 (21.3 – 28.1) | 0.418 |
| Smoking, n (%)\* | 43 (21.6) | 39 (16.5) | 0.362 |
| Diabetes, n (%) | 10 (5.0) | 12 (5.1) | 1.000 |
| Lymph Node Surgery, n (%)° |  |  |  |
| None | 16 (8.0) | 29 (12.2) | <0.001 |
| SLNB | 117 (58.8) | 180 (75.9) |  |
| TAS | 16 (8.0) | 10 (4.2) |  |
| ALND | 49 (24.6) | 18 (7.6) |  |
| Chemotherapy, n (%)° |  |  |  |
| No chemotherapy | 132 (66.3) | 183 (77.2) | 0.061 |
| Adjuvant chemotherapy | 42 (21.1) | 35 (14.8) |  |
| Neoadjuvant chemotherapy | 22 (11.1) | 18 (7.6) |  |
| Both | 3 (1.5) | 1 (0.4) |  |
| Time to adjuvant chemotherapy, median (Q1 – Q3), d  N = 74 | 40.0 (32.0 – 56.0) | 39.0 (30.0 – 55.0) | 0.753 |
| Adjuvant radiotherapy, n (%) | 142 (71.4) | 146 (61.6) | 0.034 |
| Time to adjuvant radiotherapy, median (Q1 – Q3), d  N = 192 | 51.0 (40.5 – 63.0) | 46.0 (37.5 – 55.0) | 0.015 |
| Time to adjuvant treatment, median (Q1-Q3), d  N = 266 | 49.0 (38.0 – 61.0) | 46.0 (35.0 – 55.0) | 0.069 |
| Missing: °1, \*28 | | | |